CA
AVDL

Claro Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Claro Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,200
Closed -$134K – 492
2024
Q3 		$134K Sell
10,200
-43
-0.4% -$655 0.02% 502
2024
Q2 		$144K Buy
10,243
+78
+0.8% +$1.27K 0.02% 419
2024
Q1 		$172K Buy
+10,165
New +$151K 0.03% 411
2019
Q1 		– Sell
-1,000
Closed -$4K – 204
2018
Q4 		$4K Buy
+1,000
New +$3.4K ﹤0.01% 806

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Claro Advisors's AVDL Position: Q4 2024 in Review

Claro Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q4 2024, closing a stake of 10,200 shares — an estimated $134K sold.

Claro Advisors first reported a position in AVDL in Q4 2018 and held it in 4 quarters. The position peaked at $172K in Q1 2024. 159 funds tracked by Wall St. Rank hold AVDL as of Q4 2024.

  • Claro Advisors reported no remaining Avadel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Claro Advisors sold 10,200 Avadel Pharmaceuticals shares in Q4 2024, an estimated $134K.
  • Claro Advisors first reported a position in Avadel Pharmaceuticals in Q4 2018 and held it in 4 quarters.
  • Claro Advisors's Avadel Pharmaceuticals position peaked at $172K in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2024.

Based on Claro Advisors's 13F filing for Q4 2024, filed 13 Jan 2025.